[go: up one dir, main page]

AU2002213588A1 - Soluble cd1 compositions and uses thereof - Google Patents

Soluble cd1 compositions and uses thereof

Info

Publication number
AU2002213588A1
AU2002213588A1 AU2002213588A AU1358802A AU2002213588A1 AU 2002213588 A1 AU2002213588 A1 AU 2002213588A1 AU 2002213588 A AU2002213588 A AU 2002213588A AU 1358802 A AU1358802 A AU 1358802A AU 2002213588 A1 AU2002213588 A1 AU 2002213588A1
Authority
AU
Australia
Prior art keywords
soluble
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213588A
Inventor
Samuel M. Behar
Michael B. Brenner
Jenny E. Gumperz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2002213588A1 publication Critical patent/AU2002213588A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/4285—Lipids; Lipoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002213588A 2000-06-05 2001-06-05 Soluble cd1 compositions and uses thereof Abandoned AU2002213588A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20941600P 2000-06-05 2000-06-05
US60/209416 2000-06-05
PCT/US2001/018178 WO2001094949A2 (en) 2000-06-05 2001-06-05 Soluble cd1 compositions and uses thereof

Publications (1)

Publication Number Publication Date
AU2002213588A1 true AU2002213588A1 (en) 2001-12-17

Family

ID=22778668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213588A Abandoned AU2002213588A1 (en) 2000-06-05 2001-06-05 Soluble cd1 compositions and uses thereof

Country Status (3)

Country Link
US (1) US20020071842A1 (en)
AU (1) AU2002213588A1 (en)
WO (1) WO2001094949A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE536185T1 (en) 2001-03-26 2011-12-15 Dana Farber Cancer Inst Inc METHOD FOR ATTENUATE REACTIONS TO SKIN IRRITANTS
AU2003216184A1 (en) * 2002-02-05 2003-09-02 The Regents Of The University Of California Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
EP1413316A1 (en) * 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
US9809654B2 (en) * 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
CA2584971C (en) 2004-11-02 2013-08-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for inhibition of nkt cells
US9295722B2 (en) * 2005-01-28 2016-03-29 The Scripps Research Institute Bacterial glycolipid activation of CD1d-restricted NKT cells
US20100035843A1 (en) * 2007-02-12 2010-02-11 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
CA2678618C (en) * 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
CN102325875B (en) 2009-01-08 2018-04-10 阿尔伯爱因斯坦医学有限公司 Bacterial vaccine and its application with cell wall-bound ceramide type glycolipid
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
EP2949339A1 (en) * 2014-05-29 2015-12-02 Ospedale San Raffaele S.r.l. Agonist of CD1c-restricted T cells and uses thereof
WO2016179472A2 (en) * 2015-05-07 2016-11-10 University Of Maryland, Baltimore Modulation of natural killer cell tolerance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69525058D1 (en) * 1994-10-13 2002-02-21 Brigham & Womens Hospital PRESENTATION OF LIPOARABINOMANNAN ANTIGENS TO T CELLS BY CD1 MOLECULES

Also Published As

Publication number Publication date
WO2001094949A2 (en) 2001-12-13
US20020071842A1 (en) 2002-06-13
WO2001094949A3 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
AU2001294814A1 (en) Pumpcn compositions and uses thereof
AU2001250875A1 (en) Anti-microbial and immunostimulating composition
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2002357119A1 (en) Mitocidal compositions and methods
AU2001296443A1 (en) Compositions comprising arabinogalactan and a defined protein component
AU2001287898A1 (en) Pyrazolopyridines and pyrazolopyridazines as antidiabetics
AU2001280604A1 (en) Compositions comprising icariside i and anhydroicaritin and methods for making the same
EP1151667A3 (en) Plant-activating agent
AU2002211717A1 (en) Stresscopins and their uses
AU2001272011A1 (en) Siderophores-producing bifidobacteria thereby and uses thereof
AU2002220419A1 (en) Prolamin-based sustained-release compositions and delayed-onset compositions
AU2002213588A1 (en) Soluble cd1 compositions and uses thereof
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2002357748A1 (en) Osteopontin-related compositions and methods
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU1152601A (en) Compositions and their use
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
GB9922135D0 (en) Compositions and uses
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2001262928A1 (en) Pharmaceutical compositions and their use
AU2001232080A1 (en) Compound, compositions and use
AU2000251520A1 (en) Antiviral methods and compositions
AU2001277519A1 (en) Bio-probes and use thereof
AU2001284465A1 (en) Tetraphenylporphyrin derivatives and compositions comprising the same